NeoGenomics reports Q2 adjusted EPS (19c), consensus (11c)

Reports Q2 revenue $147M, consensus $137.42M. “Our team delivered another excellent quarter with double-digit growth in both our Clinical Services and Advanced Diagnostics businesses,” said Chris Smith, Chief Executive Officer of NeoGenomics. “Building on our focused initiatives we implemented in the second half of 2022, our strategic priorities continue to drive accelerated growth supported by improvements in execution. This strong positioning provides us with significant opportunity to carry our strength forward into the second half of 2023.”